Chapter 2.5

Subject Monitoring Protocols

Comprehensive monitoring guidelines for safe and effective peptide therapy management

Clinical

Monitoring

Safety

Protocols

Monitoring Principles

• Baseline labs establish reference points for safety monitoring
• Regular follow-up allows dose optimization and early detection of adverse effects
• Subject symptoms are as important as lab values
• Document everything for continuity of care and outcome tracking

Essential Lab Panel for Peptide Therapy

Recommended baseline panel for most peptide protocols

Metabolic

• Fasting Glucose
• HbA1c
• Fasting Insulin
• Lipid Panel (with ApoB)

Hormonal

• IGF-1
• TSH, Free T4
• Total/Free Testosterone
• Estradiol (if indicated)

Safety

• CBC with Differential
• CMP (kidney/liver)
• PSA (males >40)
• Lipase (if GLP-1)

Protocol-Specific Monitoring

GH Secretagogues

Ipamorelin, CJC-1295, Tesamorelin, MK-677

Baseline Assessment

Test	Target	Action Level
IGF-1	Document baseline	>300 ng/mL: do not start
Fasting Glucose	<100 mg/dL	>126: evaluate diabetes
HbA1c	<5.7%	>6.5%: diabetes workup
Lipid Panel	Document baseline	N/A
PSA (males >40)	<4.0 ng/mL	>4.0: urology consult

Ongoing Monitoring

Test	Target	Frequency	Action Level
IGF-1	150-250 ng/mL	4 weeks, then q12w	>300: reduce dose
Fasting Glucose	<100 mg/dL	q4-8w initially	>126: adjust protocol
HbA1c	<5.7%	q12w	Rising trend: reduce dose or add metformin
Weight/Body Comp	Trending improvement	Monthly	No change at 12w: reassess
BP	<130/80	Each visit	>140/90: evaluate

Clinical Warnings

• Monitor for carpal tunnel symptoms (numbness, tingling)
• Watch for peripheral edema in first 2-4 weeks
• Morning joint stiffness usually resolves with continued use
• If IGF-1 >300 ng/mL, reduce dose and recheck in 4 weeks

Suggested Visit Schedule

Baseline

Before starting protocol

• Complete history & physical
• Baseline labs
• Subject education
• Goal setting

Week 4

Early assessment

• Tolerability check
• Early response labs
• Dose adjustment
• Side effect management

Week 8-12

Efficacy assessment

• Comprehensive labs
• Efficacy evaluation
• Protocol optimization
• Continue/modify decision

Ongoing

Every 8-12 weeks

• Monitoring labs
• Outcome tracking
• Safety surveillance
• Long-term planning

Red Flags Requiring Immediate Attention

Severe abdominal pain: Pancreatitis (GLP-1)

Persistent vomiting: Dehydration, AKI risk

Hypoglycemia symptoms: Adjust concomitant diabetes meds

Severe headache (Cerebrolysin): Reduce dose, evaluate

Signs of infection at injection site: Evaluate, may need antibiotics

New cardiac symptoms: ECG, cardiac workup

Manic symptoms (Semax): Discontinue immediately

IGF-1 >350 ng/mL: Stop GH peptides, reassess

Visit Documentation Template

Subjective

• Current symptoms/concerns
• Protocol adherence
• Side effects experienced
• Perceived efficacy
• Sleep, energy, mood

Objective

• Vital signs (BP, HR, Weight)
• Lab results review
• Physical exam findings
• Injection site assessment
• Body composition (if tracking)

Assessment

• Response to therapy
• Side effect severity
• Lab trend analysis
• Goal progress

Plan

• Continue/modify protocol
• Dose adjustments
• Additional labs/imaging
• Follow-up timing
• Subject education provided

Clinical Disclaimer

These monitoring guidelines represent best practices based on available evidence and clinical experience. Individual patient factors may require modifications. Always use clinical judgment and adapt protocols to patient-specific circumstances.

🔗 Related Tools

Previous: Interactions

Loading dashboard...

Protocol-Specific Monitoring

GH Secretagogues

Ipamorelin, CJC-1295, Tesamorelin, MK-677

Baseline Assessment

Test	Target	Action Level
IGF-1	Document baseline	>300 ng/mL: do not start
Fasting Glucose	<100 mg/dL	>126: evaluate diabetes
HbA1c	<5.7%	>6.5%: diabetes workup
Lipid Panel	Document baseline	N/A
PSA (males >40)	<4.0 ng/mL	>4.0: urology consult

Ongoing Monitoring

Test	Target	Frequency	Action Level
IGF-1	150-250 ng/mL	4 weeks, then q12w	>300: reduce dose
Fasting Glucose	<100 mg/dL	q4-8w initially	>126: adjust protocol
HbA1c	<5.7%	q12w	Rising trend: reduce dose or add metformin
Weight/Body Comp	Trending improvement	Monthly	No change at 12w: reassess
BP	<130/80	Each visit	>140/90: evaluate

Clinical Warnings

• Monitor for carpal tunnel symptoms (numbness, tingling)
• Watch for peripheral edema in first 2-4 weeks
• Morning joint stiffness usually resolves with continued use
• If IGF-1 >300 ng/mL, reduce dose and recheck in 4 weeks

Suggested Visit Schedule

Baseline

Before starting protocol

• Complete history & physical
• Baseline labs
• Subject education
• Goal setting

Week 4

Early assessment

• Tolerability check
• Early response labs
• Dose adjustment
• Side effect management

Week 8-12

Efficacy assessment

• Comprehensive labs
• Efficacy evaluation
• Protocol optimization
• Continue/modify decision

Ongoing

Every 8-12 weeks

• Monitoring labs
• Outcome tracking
• Safety surveillance
• Long-term planning

Peptide Assistant

Command Center BETA

Learning Journey

Monitoring Principles

Essential Lab Panel for Peptide Therapy

Metabolic

Hormonal

Safety

Protocol-Specific Monitoring

GH Secretagogues

Baseline Assessment

Ongoing Monitoring

Clinical Warnings

Suggested Visit Schedule

Baseline

Week 4

Week 8-12

Ongoing

Red Flags Requiring Immediate Attention

Visit Documentation Template

Subjective

Objective

Assessment

Plan

Clinical Disclaimer

🔗 Related Tools

Monitoring Principles

Essential Lab Panel for Peptide Therapy

Metabolic

Hormonal

Safety

Protocol-Specific Monitoring

GH Secretagogues

Baseline Assessment

Ongoing Monitoring

Clinical Warnings

Suggested Visit Schedule

Baseline

Week 4

Week 8-12

Ongoing

Red Flags Requiring Immediate Attention

Visit Documentation Template

Subjective

Objective

Assessment

Plan

Clinical Disclaimer

🔗 Related Tools

Command Center
BETA